Cargando…

Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions

Esafoxolaner is a purified afoxolaner enantiomer with insecticidal and acaricidal properties. It is combined with eprinomectin and praziquantel, nematodicidal and cestodicidal compounds, in a novel topical endectoparasiticide formulation for cats. This novel formulation was tested in four field stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Tielemans, Eric, Otsuki, Tomoko, Cheesman, Tara, Selmes, Fiona, Pfefferkorn, Anthony, Prullage, Joe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: EDP Sciences 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019569/
https://www.ncbi.nlm.nih.gov/pubmed/33812454
http://dx.doi.org/10.1051/parasite/2021018
_version_ 1783674399211126784
author Tielemans, Eric
Otsuki, Tomoko
Cheesman, Tara
Selmes, Fiona
Pfefferkorn, Anthony
Prullage, Joe
author_facet Tielemans, Eric
Otsuki, Tomoko
Cheesman, Tara
Selmes, Fiona
Pfefferkorn, Anthony
Prullage, Joe
author_sort Tielemans, Eric
collection PubMed
description Esafoxolaner is a purified afoxolaner enantiomer with insecticidal and acaricidal properties. It is combined with eprinomectin and praziquantel, nematodicidal and cestodicidal compounds, in a novel topical endectoparasiticide formulation for cats. This novel formulation was tested in four field studies, in the United States, Europe, Japan and Australia. In all studies, naturally flea-infested domestic cats were treated with the novel formulation at the label dose and conditions of use. The main objective, identical in the four studies, was to assess efficacy on fleas, based on comparison of mean number of fleas found on infested cats before and one month after treatment. Tolerance to the product was also evaluated in the four studies. Otherwise, the studies had some differences in their design and secondary objectives, for example testing for a reduction in flea infestation-related cutaneous signs, testing of one treatment or of three monthly treatments, and use of a positive control group. In the four studies, a total of 307 cats were treated with the novel formulation. The reduction of fleas one month after treatment was 97.7%, 98.8%, 100% and 99.7% in the United States, Europe, Japan and Australia, respectively. There were no significant health abnormalities attributed to treatment in any of the studies.
format Online
Article
Text
id pubmed-8019569
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher EDP Sciences
record_format MEDLINE/PubMed
spelling pubmed-80195692021-04-05 Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions Tielemans, Eric Otsuki, Tomoko Cheesman, Tara Selmes, Fiona Pfefferkorn, Anthony Prullage, Joe Parasite Research Article Esafoxolaner is a purified afoxolaner enantiomer with insecticidal and acaricidal properties. It is combined with eprinomectin and praziquantel, nematodicidal and cestodicidal compounds, in a novel topical endectoparasiticide formulation for cats. This novel formulation was tested in four field studies, in the United States, Europe, Japan and Australia. In all studies, naturally flea-infested domestic cats were treated with the novel formulation at the label dose and conditions of use. The main objective, identical in the four studies, was to assess efficacy on fleas, based on comparison of mean number of fleas found on infested cats before and one month after treatment. Tolerance to the product was also evaluated in the four studies. Otherwise, the studies had some differences in their design and secondary objectives, for example testing for a reduction in flea infestation-related cutaneous signs, testing of one treatment or of three monthly treatments, and use of a positive control group. In the four studies, a total of 307 cats were treated with the novel formulation. The reduction of fleas one month after treatment was 97.7%, 98.8%, 100% and 99.7% in the United States, Europe, Japan and Australia, respectively. There were no significant health abnormalities attributed to treatment in any of the studies. EDP Sciences 2021-04-02 /pmc/articles/PMC8019569/ /pubmed/33812454 http://dx.doi.org/10.1051/parasite/2021018 Text en © E. Tielemans et al., published by EDP Sciences, 2021 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Tielemans, Eric
Otsuki, Tomoko
Cheesman, Tara
Selmes, Fiona
Pfefferkorn, Anthony
Prullage, Joe
Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions
title Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions
title_full Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions
title_fullStr Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions
title_full_unstemmed Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions
title_short Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions
title_sort efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019569/
https://www.ncbi.nlm.nih.gov/pubmed/33812454
http://dx.doi.org/10.1051/parasite/2021018
work_keys_str_mv AT tielemanseric efficacyofanoveltopicalcombinationofesafoxolanereprinomectinandpraziquantelagainstfleasincatsunderfieldconditions
AT otsukitomoko efficacyofanoveltopicalcombinationofesafoxolanereprinomectinandpraziquantelagainstfleasincatsunderfieldconditions
AT cheesmantara efficacyofanoveltopicalcombinationofesafoxolanereprinomectinandpraziquantelagainstfleasincatsunderfieldconditions
AT selmesfiona efficacyofanoveltopicalcombinationofesafoxolanereprinomectinandpraziquantelagainstfleasincatsunderfieldconditions
AT pfefferkornanthony efficacyofanoveltopicalcombinationofesafoxolanereprinomectinandpraziquantelagainstfleasincatsunderfieldconditions
AT prullagejoe efficacyofanoveltopicalcombinationofesafoxolanereprinomectinandpraziquantelagainstfleasincatsunderfieldconditions